Product List
Product List
Here you can find an overview of all the products that we offer in Canada.
Canadian regulations limit what information we are permitted to provide about our products via the Internet. Please consult a qualified health professional for more detailed information.
The Product Monograph (Product Information) and/or the Product Packaging currently available in the Canadian market might differ from the latest approved Product Monograph (Product Information) and/or Product Packaging. The latest approved versions will be made available to the Canadian market in due time.
If you have any questions or comments please contact us at CSL Behring Canada at 1-866-773-7721.
Immunology
| Hizentra® | Immune Globulin Subcutaneous (Human) 20% Liquid Product Monograph |
| Privigen® | Immune Globulin Intravenous (Human), 10% Liquid Product Monograph |
Hematology
| PrHEMGENIX® | Etranacogene dezaparvovec Product Monograph |
| Humate-P® | Antihemophilic Factor/von Willebrand Factor Complex (Human) Product Monograph |
| RiaSTAP™ | Fibrinogen Concentrate (Human) Product Monograph |
| IDELVION™ | Coagulation Factor IX (Recombinant) Albumin Fusion Protein Product Monograph |
| Corifact™ | Factor XIII Concentrate (Human) Product Monograph |
Specialty Care
| Berinert® 500 / Berinert® 1500 | C1-Esterase Inhibitor, Human Product Monograph |
| HAEGARDA® | C1-Esterase Inhibitor Subcutaneous, (Human) Product Monograph |
| Beriplex® P/N 500 / Beriplex® P/N 1000 | Human Prothrombin Complex Product Monograph |
| Alburex® 5, Alburex® 25 | Human Albumin Product Monograph |
| Zemaira®, Alpha1-Proteinase Inhibitor (Human) Product Monograph |
Iron Deficiency
| Ferinject ® Product Monograph |
The trademarks marked ® are registered by CSL Limited or its affiliates or subsidiaries in one or more jurisdictions, unless indicated otherwise.
Report an adverse drug reaction
If you have encountered any side effect(s) from a CSL Behring product, we encourage you to talk to your doctor, pharmacist, or nurse.
CSL Behring also collects information about adverse drug reactions in order to monitor product safety and investigate, evaluate and report adverse drug reactions to appropriate regulatory bodies.